Company intelligence / Profile preview

DISruptive Oncology

Uppsala, Uppsala län, Swedenhealio.com ↗

Ownership: Private
Development stage: Other

Overview

Disruptive Pharma develops better and safer medicines using its proprietary MMC technology, which creates amorphous versions of existing drugs with improved bioavailability. Its lead product DPH001—an MMC-improved version of sorafenib—is set to enter clinical trials for liver and kidney cancer in late 2024. The company pursues both internal development and partnerships/co-development opportunities, focusing on de-risked development paths by improving established medicines rather than developing new chemical entities from scratch. Additional pipeline programs are planned but not yet disclosed publicly.

Therapeutic areas: Oncology
Modalities: Small molecule (improved amorphous formulations)Amorphous drug formulation technology (MMC-based)
Industry: Biotech

Partnerships

Seeking partners for commercialization of lead asset DPH001; no specific partners named yet.

Beyond the preview

Go deeper on DISruptive Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DISruptive Oncology.

Explore the full profile